MEDP vs. REGN: Medpace vs. Regeneron Pharmaceuticals Stock Comparison
How do Medpace (MEDP) and Regeneron Pharmaceuticals (REGN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Medpace (MEDP) and Regeneron Pharmaceuticals (REGN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MEDP is classified in Life Sciences Tools & Services while REGN is classified in Biotechnology.
| Profile Item | MEDP | REGN |
|---|---|---|
| Name | Medpace Holdings, Inc. | Regeneron Pharmaceuticals, Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Biotechnology |
| GICS Sub-Industry | Life Sciences Tools & Services | Biotechnology |
| Market Capitalization | 18.27 billion USD | 93.55 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | August 11, 2016 | April 2, 1991 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | MEDP | REGN |
|---|---|---|
| Total Return (1Y) | 13.29% | 40.87% |
| Total Return (3Y, Annualized) | 35.26% | 5.15% |
| Total Return (5Y, Annualized) | 24.49% | 8.58% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | MEDP | REGN |
|---|---|---|
| Volatility (1Y, Annualized) | 44.16% | 34.08% |
| Beta (5Y) | 1.10 | 0.10 |
| Max Drawdown (5Y) | -42.87% | -59.69% |
| Avg. Volume (3M) | 258.39K | 772.95K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | MEDP | REGN |
|---|---|---|
| Sharpe Ratio (1Y) | 0.20 | 1.07 |
| Sortino Ratio (1Y) | 0.26 | 1.70 |
Profitability
ROE (TTM)
Both companies show strong equity returns, but Medpace (MEDP) at 117.88% is the standout with ROE above its industry range; Regeneron Pharmaceuticals (REGN) at 14.95% also sits in the top quartile.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
117.88%
- MEDP
- 117.88%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.95%
- Max
- 109.18%
- REGN
- 14.95%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Medpace (MEDP) at 18.24% and Regeneron Pharmaceuticals (REGN) at 28.51% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.24%
- MEDP
- 18.24%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.51%
- REGN
- 28.51%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Medpace (MEDP) at 23.12% and Regeneron Pharmaceuticals (REGN) at 40.46% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.12%
- Max
- 83.12%
- MEDP
- 23.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
40.46%
- Max
- 83.12%
- REGN
- 40.46%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | MEDP | REGN |
|---|---|---|
| ROE (TTM) | 117.88% | 14.95% |
| ROA (TTM) | 18.71% | 7.59% |
| Net Margin (TTM) | 18.24% | 28.51% |
| Operating Margin (TTM) | 23.12% | 40.46% |
| Gross Margin (TTM) | 72.24% | 46.73% |
Growth
Revenue Growth
Both Medpace (MEDP) at 19.97% and Regeneron Pharmaceuticals (REGN) at 0.99% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Both Medpace (MEDP) at 20.98% and Regeneron Pharmaceuticals (REGN) at 8.19% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | MEDP | REGN |
|---|---|---|
| Revenue Growth (YoY) | 19.97% | 0.99% |
| Revenue Growth (3Y CAGR) | 20.12% | 5.62% |
| EPS Growth (YoY) | 20.98% | 8.19% |
| EPS Growth (3Y CAGR) | 28.04% | 2.77% |
Financial Strength
Current Ratio (MRQ)
Regeneron Pharmaceuticals (REGN) at 3.35 keeps current ratio within its industry’s typical mid-range, while Medpace (MEDP) at 0.83 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MEDP.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.83
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- MEDP
- 0.83
- Min
- 0.10
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.35
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- REGN
- 3.35
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Medpace (MEDP) at 0.29 and Regeneron Pharmaceuticals (REGN) at 0.08 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.29
- Max
- 1.42
- Q3
- 0.65
- MEDP
- 0.29
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.08
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- REGN
- 0.08
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | MEDP | REGN |
|---|---|---|
| Current Ratio (MRQ) | 0.83 | 3.35 |
| Debt / Equity (MRQ) | 0.29 | 0.08 |
| Net Debt / EBITDA | -0.84 | -1.17 |
Dividends
Dividend Yield (TTM)
Medpace (MEDP) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a yield of 0.41%, ranking against industry peers normally.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MEDP
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.41%
- REGN
- 0.41%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Medpace (MEDP) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a payout of 8.18%, ranking against industry peers normally.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MEDP
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.18%
- REGN
- 8.18%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | MEDP | REGN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.41% |
| Dividend Payout Ratio (TTM) | 0.00% | 8.18% |
Valuation
P/E Ratio (TTM)
Both Medpace (MEDP) at 36.26 and Regeneron Pharmaceuticals (REGN) at 19.99 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.26
- Max
- 85.34
- Q3
- 43.46
- MEDP
- 36.26
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.99
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- REGN
- 19.99
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Medpace (MEDP) at 6.44 and Regeneron Pharmaceuticals (REGN) at 5.54 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.44
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- MEDP
- 6.44
- Q1
- 3.01
- Min
- 0.01
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.54
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- REGN
- 5.54
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Regeneron Pharmaceuticals (REGN) at 2.71 sits near its industry’s typical P/B ratio, while Medpace (MEDP) at 31.23 prices above its benchmark range — MEDP looks rich relative to book.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.23
- MEDP
- 31.23
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.71
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- REGN
- 2.71
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | MEDP | REGN |
|---|---|---|
| P/E Ratio (TTM) | 36.26 | 19.99 |
| P/S Ratio (TTM) | 6.44 | 5.54 |
| P/B Ratio (MRQ) | 31.23 | 2.71 |
| Free Cash Flow Yield (TTM) | 2.72% | 2.76% |